Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christel M P van Dongen

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|December 20, 2012
[The happy doctor]Christel M P van Dongen, Yolanda van der Graaf
Nederlands Tijdschrift Voor Geneeskunde|October 16, 2012
[Behçet and his triad]Christel M P van Dongen, Joost P Gijselhart, Jan van Gijn
British Journal of Clinical Pharmacology|February 15, 2023
Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is moreNiels W Boone, Dirk Jan A R Moes, Sofia Ramiro, et al.
Annals of the Rheumatic Diseases|July 29, 2020
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studySofia Ramiro, Rémy L M Mostard, César Magro-Checa, et al.
Clinical Chemistry and Laboratory Medicine|February 8, 2021
Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzerRemy J H Martens, Arjan J van Adrichem, Nadine J A Mattheij, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Nederlands Tijdschrift Voor Geneeskunde|December 20, 2012
[The happy doctor]Christel M P van Dongen, Yolanda van der Graaf
Nederlands Tijdschrift Voor Geneeskunde|October 16, 2012
[Behçet and his triad]Christel M P van Dongen, Joost P Gijselhart, Jan van Gijn
British Journal of Clinical Pharmacology|February 15, 2023
Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is moreNiels W Boone, Dirk Jan A R Moes, Sofia Ramiro, et al.
Annals of the Rheumatic Diseases|July 29, 2020
Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studySofia Ramiro, Rémy L M Mostard, César Magro-Checa, et al.
Clinical Chemistry and Laboratory Medicine|February 8, 2021
Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzerRemy J H Martens, Arjan J van Adrichem, Nadine J A Mattheij, et al.
Pageof 1